The familiar question in genetic politics is who owns your DNA. It is no longer the most revealing one. A more exact question, by mid-2026, is who controls what can be built from digitised biology once a sequence has been read, copied, modelled, ordered and assembled. DNA is becoming less a record to be stored than a substrate to be used.
That shift matters because the legal tools built for the first era of genomics were designed around secrecy, consent and discrimination. They asked whether insurers, employers, police, hospitals or researchers could access identifiable genetic information. The second era is organised around a different chain of value. Sequence data move into training sets, design software, synthesis pipelines, patent claims, public databases and distributed laboratories. The crucial asymmetry is not only who holds data, but who can convert data into biological capability.
This is why the ownership debate now feels oddly mis-specified. Individuals can possess rights over samples, privacy interests in identifiable data and, in some jurisdictions, limited powers of consent or withdrawal. Yet none of that straightforwardly governs whether others may design a protein using published sequence information, reconstruct a pathogen from digital fragments, or claim proprietary rights over a modified biological system derived from material that once sat inside another person, species or ecosystem.
From personal information to production input
Privacy law treats genomic data as sensitive because it can identify people, reveal kinship and imply future health risks. That remains true. But synthetic biology treats sequence information differently: as machine-readable instruction. Once rendered as code, DNA no longer sits only in the institutional spaces of medicine and research. It enters supply chains for oligonucleotides, cloud-based modelling, automated laboratory workflows and intellectual-property portfolios.
The consequence is not the end of privacy but its downgrading as the sole organising principle. A person may consent to clinical sequencing under strict hospital governance, while the scientifically useful patterns extracted from many genomes migrate into less clearly bounded industrial and research settings. Even when data are de-identified, the functional lessons can remain commercially and strategically powerful. Law is generally better at regulating personal records than design knowledge.
DNA is becoming less a record to be stored than a substrate to be used.
Why the old ownership metaphor misleads
Courts and legislators have long been uneasy with the language of owning bodies and body parts. In the United States, the Supreme Court held in Association for Molecular Pathology v. Myriad Genetics that naturally occurring DNA segments are products of nature and not patent eligible merely because they have been isolated, though complementary DNA could under some circumstances qualify. That ruling narrowed one route for claiming exclusive rights over genes as discoveries.
Yet the practical frontier has moved. Fewer serious actors now argue for property rights over a naturally occurring sequence as such. Instead, exclusivity is sought through engineered constructs, methods of use, platform know-how, data control, contractual restrictions and scale advantages in synthesis and testing. Biological ownership is increasingly asserted at the point of design, not discovery.
This distinction is easy to miss because public debate still gravitates to the older image of a corporation patenting a human gene. The more consequential pattern is subtler: rights and power collecting around the capacity to transform openly available or lawfully accessed sequence information into high-value applications. Ownership is becoming infrastructural.
The rise of digital sequence information as a geopolitical fault-line
No issue illustrates the new politics more clearly than digital sequence information, often shortened to DSI, in the biodiversity negotiations under the Convention on Biological Diversity. States rich in biodiversity have argued that if genetic resources can be dematerialised into digital data and used elsewhere for research and commercial development, existing benefit-sharing bargains are undermined. Users may no longer need physical access to samples from the country of origin in order to extract value.
DNA is becoming less a record to be stored than a substrate to be used.
That argument has implications well beyond rainforests and marine bioprospecting. It suggests that the key legal asset is not merely the molecule in a vial but the informational and design capacity abstracted from it. Once value can be generated from sequence databases alone, classic access-and-benefit-sharing regimes look incomplete. They were built for a world in which control over physical specimens provided leverage.
The DSI debate therefore foreshadows a broader constitutional problem for biotechnology governance. If biological innovation can be detached from the place, person or community from which the underlying sequence originated, what remains of origin-based rights? International negotiators are trying to answer that through new benefit-sharing mechanisms, but the underlying pressure comes from a deeper technological fact: biological value now travels digitally first.
Health data regimes are necessary but no longer sufficient
Europe's health-data architecture, including the European Health Data Space, and the OECD's work on health data governance respond to legitimate needs for interoperability, research access, individual rights and public trust. They are important because healthcare systems increasingly rely on large-scale genomic datasets for diagnosis and population medicine. But these frameworks are built chiefly around the lawful use of health information, not the governance of downstream biological design.
A database can be impeccably governed as health data and still feed capabilities that raise different questions. Should models trained on genomic and proteomic information be treated purely as informational outputs, or as dual-use assets with biosecurity significance? Should data access committees consider not only privacy harms but also the possibility of enabling high-consequence synthesis? Existing systems tend to separate these domains institutionally: ethics for patients, export control for goods, biosecurity for pathogens, patents for inventions. The technology is dissolving those boundaries faster than law is updating them.
This mismatch helps explain why genetic-rights debate often feels stale. It describes the front door while power is moving through the workshop at the back.
Gene synthesis turns sequence access into real-world capability
The practical bridge between digital information and physical biology is gene synthesis. Improvements in the speed, scale and geographical spread of synthesis services mean that the ability to order nucleic acids is now a central governance chokepoint. Screening frameworks, including the United States government's 2024 framework for nucleic acid synthesis screening, recognise that dangerous capability can emerge not only from possession of pathogens but from the ability to reconstruct or modify them from sequence information.
This changes the meaning of control. In an earlier era, restricting access to biological agents was a primary security strategy. In the current one, sequence publication, open databases and synthesis markets make that strategy incomplete. Governance has to operate across customer screening, sequence screening, anomaly detection, provenance and reporting. None of these are simple substitutes for privacy law or patent law, because their object is not ownership or confidentiality. It is the prevention of harmful construction.
The crucial asymmetry is not only who holds data, but who can convert data into biological capability.
The policy difficulty is that much of the same infrastructure serves benign science and public health. During outbreaks, rapid sharing of pathogen sequences is essential. The World Health Organisation's guidance on responsible life-sciences use stresses precisely this tension: openness can accelerate both protection and misuse. A mature genetic-rights framework therefore cannot be a pure liberty model or a pure security model. It must account for the fact that the same string of bases can be at once clinical information, research input, commercial raw material and dual-use code.
AI compresses the distance between sequence and invention
Artificial intelligence does not remove the need for laboratory work, but it compresses search costs in biological design. Models can propose candidate proteins, optimise sequences and help navigate vast combinatorial spaces. The legal system is not well prepared for inventions that are partly derived from public or pooled biological data and partly from model-guided exploration performed at scale.
The crucial asymmetry is not only who holds data, but who can convert data into biological capability.
This intensifies an existing imbalance. Communities, patients and biodiverse states often contribute the underlying material from which knowledge is abstracted. But the economically defensible position may arise later, when a better-capitalised actor uses advanced computation and synthesis to generate patentable applications or protected trade secrets. The passage from sample to sequence to design model to manufactured biological system creates multiple points at which rights can be detached from original sources.
That does not make all proprietary claims illegitimate. Translation from sequence insight to a safe and useful therapy, diagnostic or industrial organism can require substantial inventive effort. The problem is governance opacity. Current frameworks rarely require a clear accounting of how upstream genetic resources, public databases and collective contributions are transformed into downstream exclusivities. In practice, benefits may accrue where design and scaling occur rather than where data or biological material originated.
What individuals can claim, and what they usually cannot
For individuals, this emerging landscape produces an uncomfortable truth. You may hold rights against certain forms of misuse of your genetic information. You may, in some contexts, be protected against discrimination. You may be able to consent to or refuse participation in specific studies. But you generally do not possess a durable property claim over every derivative use, inference, model parameter or biological design that can ultimately be linked, however distantly, to data from your body.
That gap is not simply a policy oversight. It reflects the structure of knowledge production. Genetic data become most valuable when aggregated across many people and interpreted statistically. The resulting utility often lies in population-level associations or functional design rules rather than in any one person's sequence. Legal systems have therefore hesitated to grant expansive ownership rights to individuals over informational derivatives, fearing they would impede research and create impossible tracing burdens.
Still, the absence of property rights does not mean the absence of justice claims. The stronger argument is less that a person owns every downstream use of their DNA than that institutions using genomic resources should be accountable for benefit-sharing, transparency, governance and limits on high-risk applications. Rights may need to look more fiduciary than proprietary.
Synthetic biology exposes the weakness of consent as a master principle
Consent remains ethically important, but it is a poor master principle for a technological environment in which future uses are difficult to specify, actors are numerous and innovation pathways are indirect. A participant can consent to data use in broad terms without meaningfully understanding that aggregate insights may contribute to protein engineering, agricultural traits, forensic tools or dual-use capabilities far removed from the initial context.
For this reason, some of the most serious governance questions cannot be solved by better forms alone. They concern institutional responsibility after consent has been obtained: restrictions on secondary use, obligations to reassess risk, independent oversight for dual-use research, conditions on access to synthesis services, and benefit-sharing models that do not depend on tracing every contribution with impossible precision.
The older promise of consent-based genomic governance was that if people were informed and agreed, legitimacy would follow. In the age of biological design, legitimacy depends increasingly on what systems do after data have lawfully entered them.
Patent law is only one piece of biological power
Discussion of genetic ownership often overstates the role of patents and understates the role of trade secrets, contracts and tacit know-how. Patent doctrine still matters greatly because it sets boundaries around what kinds of biological inventions can receive exclusive rights and under what disclosure obligations. But many strategic advantages in synthetic biology arise from proprietary datasets, model tuning, manufacturing processes, quality systems and customer relationships that do not appear in patent registers.
This matters politically because patent law is comparatively visible and contestable. It contains public claims, examination records and expiry dates. Infrastructural control hidden in private agreements or closed technical workflows is harder to scrutinise. If sovereignty over biology is becoming a matter of who can reliably design and make things, states may find that conventional debates about patent eligibility miss where dependency is actually forming.
Biological ownership is increasingly asserted at the point of design, not discovery.
In that sense, genetic rights are converging with industrial policy. The question is no longer only whether genes can be owned, but whether crucial layers of the bioeconomy become governed by a small number of technical bottlenecks beyond effective public oversight.
A better frame is stewardship over biological capability
If ownership is the wrong metaphor and privacy is too narrow, what should replace them. A plausible answer is stewardship of biological capability. That frame begins from the recognition that genomic information now participates in systems able to produce interventions in health, agriculture, materials and security. The aim is not to assign simple title over DNA, but to govern the transitions from source material to digital sequence, from sequence to design, and from design to synthesis.
Stewardship would involve several layers. One is equitable benefit-sharing for the use of genetic resources and associated digital information, especially where public and indigenous contributions are foundational. Another is robust health-data governance for identifiable and sensitive information. A third is biosecurity oversight at the level of synthesis, model access and laboratory practice. A fourth is transparency in how downstream exclusivities are built from upstream public or shared resources.
These layers do not collapse into one another. That is precisely the point. The genomics era encouraged a habit of treating many problems as privacy problems. The synthetic-biology era reveals a wider field of control points.
What this means for sovereignty in the late-genomic age
For states, the emerging fault-line is strategic as much as ethical. Nations that focus only on protecting citizens' data may still lose leverage if they lack influence over sequence repositories, standards for synthesis screening, computational design infrastructure and the legal architecture of benefit-sharing. Conversely, aggressive control over data without trusted research and public-health pathways can leave a country scientifically marginal while doing little to reduce global risk.
Sovereignty here is not autarky. It is the capacity to shape the rules linking genetic information to material capability. That includes setting terms for cross-border use of biodiversity-related sequence information, participating in international screening norms, building credible public-interest governance for health genomics and ensuring that proprietary rights do not wholly displace obligations to safety and fairness.
The deeper lesson is that biological power now accumulates downstream. Those who can design, synthesise and scale biological systems command the decisive position, even when the upstream sequences are public, shared or ethically sourced. Ownership disputes will therefore keep returning, but increasingly as proxies for a larger contest over conversion capacity.
The question after privacy
The language of who owns your DNA captured an early anxiety of the genomic age: that intimate information might be taken, exposed or monopolised. That concern has not disappeared. Yet by mid-2026, it no longer captures the most consequential terrain. The frontier problem is how legal and technical systems govern the passage from genetic information to biological construction.
That shift demands a harder realism. Open science can generate public value while also diffusing capability. Intellectual property can reward genuine invention while also concentrating control far from the origins of biological knowledge. Consent can respect autonomy while leaving collective downstream effects ungoverned. None of these tensions can be resolved by asking who owns a sequence in the abstract.
Biological ownership is increasingly asserted at the point of design, not discovery. The institutions that matter most are therefore not only those that guard files and samples, but those that supervise synthesis, allocate benefit, discipline high-risk experimentation and decide what kinds of biological construction are legitimate. In the next phase of genetic politics, control over what can be built will matter more than title over what was found.
